MedTrace Logo

Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone.

NCT07367425 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-01-26

No results posted yet for this study

Summary

In primary adrenal insufficiency (PAI), there is a risk of hypoglycemia and dehydration. These risks seem to be increased during intermittent fasting. A previous study in patients with PAI treated with hydrocortisone at a dose of 20 mg/day showed that the prevalence of hypoglycemia was as high outside (63%) as during Ramadan fasting (71%), and that there was no risk of dehydration. We propose to evaluate the risk of complications during and outside of Ramadan fasting through a prospective study with subjects taken as their own controls, in 35 patients with PAI treated with prednisolone at a dose of 5 mg/day. Patients will undergo an interview, physical examination, blood sampling, and continuous glucose monitoring (CGM) during two weeks of fasting and two weeks of non-fasting.

Conditions

  • Primary Adrenal Insufficiency
  • Ramadan Fasting
  • Prednisolone
  • Continuous Glucose Monitoring
  • Hypoglycemia Non-Diabetic
  • Dehydration

Interventions

OTHER

Ramadan fasting

Ramadan fasting is a religious dry intermittent fasting

Sponsors & Collaborators

  • Hopital La Rabta

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-22
Primary Completion
2026-03-22
Completion
2026-03-30

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07367425 on ClinicalTrials.gov